Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study
5 affiliations
- 1Department of Cardiology, Hypertension and Internal Diseases, Mazovian Brodnowski Hospital, Medical University of Warsaw, Warsaw, Poland
- 2Department of Sports Cardiology and Noninvasive Cardiovascular Imaging, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
- 3Bioinformatics Facility, International Institute of Molecular and Cell Biology, Poland
- 4Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland
- 5Department of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Warsaw, Poland
Abstract
Background: Myocardial infarction (MI) induces cardiac remodeling and lead to heart failure. Some patients experience reverse remodeling, characterized by improved LV function. MicroRNAs (miRNAs) regulate gene expression and play a crucial role in remodeling processes. Objectives: We aimed to investigate the role of miRNAs in cardiac reverse remodeling after MI and identify candidate miRNAs that could predict better response to cardiac rehabilitation. Methods: The study enrolled 39 patients following their first MI. For final analysis, 10 patients meeting echocardiographic criteria for LVRR at 8-week follow-up (absolute LVEF increase ≥ 10% or LVESV reduction ≥ 15%) were matched with 10 patients with stable LV status (SLVS). All patients completed a cardiac rehabilitation program. Expression of 375 circulating miRNAs was quantified – those with higher baseline accumulation in the LVRR group were identified as candidate biomarkers and their target genes were analyzed. Results: Twenty patients (mean age 57 ± 9 years) were analyzed. At baseline, the SLVS group exhibited significantly higher LVEF compared to the LVRR group (53% vs. 44%, p = 0.013). Baseline regional contractility impairment in all LVRR patients was reversed in 70% of them at follow-up. Fourteen miRNAs (-15b-5p, −24-3p, -29c-3p, -99b-5p, −127-3p, -146a-5p, -199a-3p, −361-5p, −502-5p, −625-5p, -376c-3p, -18b-5p, −342-5p, and −429) were identified as candidate LVRR biomarkers. Enrichment analysis linked their targets to PI3K-Akt, MAPK, FoxO, and HIF-1 pathways. Conclusions: This study identifies 14 candidate miRNAs as LVRR biomarkers post-MI. These findings highlight the biological relevance of non-coding RNA and support the need for further research and validation in large, non-pooled cohorts. Unstructured abstract: Myocardial infarction triggers adverse cardiac remodeling, though some patients achieve left ventricular reverse remodeling (LVRR), marked by functional and structural recovery. This pilot study investigated 39 patients to identify circulating microRNAs (miRNAs) that predict positive responses to cardiac rehabilitation. Comparing 10 LVRR responders against 10 stable patients, we quantified 375 miRNAs via RT-qPCR. At baseline, the stable group had higher ejection fractions (53% vs. 44%, p = 0.013), but 70% of LVRR patients reversed regional contractility impairment by the 8-week follow-up. We identified 14 potential biomarkers, including novel candidates (miR-502-5p, miR-376c-3p, and miR-18b-5p), whose target genes enrich pathways like PI3K-Akt, MAPK, and FoxO. These findings bridge the gap between preclinical data and clinical settings, highlighting the therapeutic potential of non-coding RNAs in cardiac reverse remodeling and necessitating further validation in larger cohorts.
Related
- From marrow memory to adverse ventricular remodeling: trained immunity after myocardial infarction
- Microtubule-associated protein 1S (MAP1S): a cardioprotective factor against post-myocardial infarction remodeling via apoptosis inhibition
- A NET-associated immunothrombotic phenotype is associated with coronary no-reflow and myocardial injury after primary PCI in ST-segment elevation myocardial infarction: a real-world translational cohort
- Poor survival after myocardial infarction in immune deficient NXG B2m mice is alleviated by transplantation of induced pluripotent stem cell derived cardiomyocytes (iPSC-CM) formulated as spheres, but not single cells
- Re. The influence of personality on the risk of myocardial infarction in UK Biobank cohort
BibTeX
@article{gozdowska2026circulating,
title = {{Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study}},
author = {Roksana Gozdowska and Marcin Konopka and Anna Hojka-Osińska and Grzegorz Jas and Katarzyna Czarzasta and Agnieszka Cudnoch-Jędrzejewska and Wojciech Braksator and Dominika Klimczak-Tomaniak and Marek Kuch},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0360414},
url = {https://doi.org/10.1371/journal.pone.0360414},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study
AU - Roksana Gozdowska
AU - Marcin Konopka
AU - Anna Hojka-Osińska
AU - Grzegorz Jas
AU - Katarzyna Czarzasta
AU - Agnieszka Cudnoch-Jędrzejewska
AU - Wojciech Braksator
AU - Dominika Klimczak-Tomaniak
AU - Marek Kuch
PY - 2026
DA - 2026/10/15
JO - PLOS One
DO - 10.1371/journal.pone.0360414
UR - https://doi.org/10.1371/journal.pone.0360414
AB - Background: Myocardial infarction (MI) induces cardiac remodeling and lead to heart failure. Some patients experience reverse remodeling, characterized by improved LV function. MicroRNAs (miRNAs) regulate gene expression and play a crucial role in remodeling processes. Objectives: We aimed to investigate the role of miRNAs in cardiac reverse remodeling after MI and identify candidate miRNAs that could predict better response to cardiac rehabilitation. Methods: The study enrolled 39 patients following their first MI. For final analysis, 10 patients meeting echocardiographic criteria for LVRR at 8-week follow-up (absolute LVEF increase ≥ 10% or LVESV reduction ≥ 15%) were matched with 10 patients with stable LV status (SLVS). All patients completed a cardiac rehabilitation program. Expression of 375 circulating miRNAs was quantified – those with higher baseline accumulation in the LVRR group were identified as candidate biomarkers and their target genes were analyzed. Results: Twenty patients (mean age 57 ± 9 years) were analyzed. At baseline, the SLVS group exhibited significantly higher LVEF compared to the LVRR group (53% vs. 44%, p = 0.013). Baseline regional contractility impairment in all LVRR patients was reversed in 70% of them at follow-up. Fourteen miRNAs (-15b-5p, −24-3p, -29c-3p, -99b-5p, −127-3p, -146a-5p, -199a-3p, −361-5p, −502-5p, −625-5p, -376c-3p, -18b-5p, −342-5p, and −429) were identified as candidate LVRR biomarkers. Enrichment analysis linked their targets to PI3K-Akt, MAPK, FoxO, and HIF-1 pathways. Conclusions: This study identifies 14 candidate miRNAs as LVRR biomarkers post-MI. These findings highlight the biological relevance of non-coding RNA and support the need for further research and validation in large, non-pooled cohorts. Unstructured abstract: Myocardial infarction triggers adverse cardiac remodeling, though some patients achieve left ventricular reverse remodeling (LVRR), marked by functional and structural recovery. This pilot study investigated 39 patients to identify circulating microRNAs (miRNAs) that predict positive responses to cardiac rehabilitation. Comparing 10 LVRR responders against 10 stable patients, we quantified 375 miRNAs via RT-qPCR. At baseline, the stable group had higher ejection fractions (53% vs. 44%, p = 0.013), but 70% of LVRR patients reversed regional contractility impairment by the 8-week follow-up. We identified 14 potential biomarkers, including novel candidates (miR-502-5p, miR-376c-3p, and miR-18b-5p), whose target genes enrich pathways like PI3K-Akt, MAPK, and FoxO. These findings bridge the gap between preclinical data and clinical settings, highlighting the therapeutic potential of non-coding RNAs in cardiac reverse remodeling and necessitating further validation in larger cohorts.
SN - 1932-6203
ER -